Provided By PR Newswire
Last update: Jul 15, 2025
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIRâ„¢
Read more at prnewswire.com1.21
+0.01 (+0.83%)
1.91
+0.02 (+1.06%)
Find more stocks in the Stock Screener